Education
About Us
Working with TipRanks
Follow Us
Beyond Air (XAIR)
:XAIR
XAIR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.02 - $13.52
Previous CloseN/A
Volume845.14K
Average Volume (3M)327.37K
Market Cap
$11.60M
Enterprise Value$22.82M
Total Cash (Recent Filing)$6.63M
Total Debt (Recent Filing)$11.69M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Nov 17, 2025EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding5,226,213
10 Day Avg. Volume100,989
30 Day Avg. Volume327,366
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.97
Enterprise Value/Revenue4.77
Enterprise Value/Gross Profit-19.42
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$10.50Price Target Upside375.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Market ExpansionWith newly signed distribution agreements in ex-U.S. markets, XAIR has access to over 30 countries.
Product ApprovalApproval of the second generation LungFit PH system is expected to drive substantial revenue growth and market adoption.
Sales MomentumThe company is gaining sales momentum and reiterated fiscal year 2026 guidance of $12M - $16M.
Bears Say
Cash Position ConcernsThe sustained negative pressure on the stock is being driven primarily by concerns over the company's cash position.
Delayed Revenue AchievementBeyond Air faced setbacks and challenges in its initial commercial efforts, which limited its ability to achieve substantial revenue due to delays and disruptions during the COVID-19 pandemic and a failed agreement with a partner.
Initial Commercial ChallengesBeyond Air faced setbacks and challenges in its initial commercial efforts, which limited its ability to achieve substantial revenue.
Beyond Air News
XAIR FAQ
What was Beyond Air’s price range in the past 12 months?
Beyond Air lowest stock price was $2.02 and its highest was $13.52 in the past 12 months.
What is Beyond Air’s market cap?
Beyond Air’s market cap is $11.60M.
When is Beyond Air’s upcoming earnings report date?
Beyond Air’s upcoming earnings report date is Nov 17, 2025 which is in 74 days.
How were Beyond Air’s earnings last quarter?
Beyond Air released its earnings results on Aug 12, 2025. The company reported -$1.53 earnings per share for the quarter, missing the consensus estimate of -$1.228 by -$0.302.
Is Beyond Air overvalued?
According to Wall Street analysts Beyond Air’s price is currently Undervalued.
Does Beyond Air pay dividends?
Beyond Air does not currently pay dividends.
What is Beyond Air’s EPS estimate?
Beyond Air’s EPS estimate is -0.96.
How many shares outstanding does Beyond Air have?
Beyond Air has 5,226,213 shares outstanding.
What happened to Beyond Air’s price movement after its last earnings report?
Beyond Air reported an EPS of -$1.53 in its last earnings report, missing expectations of -$1.228. Following the earnings report the stock price went down -22.468%.
Which hedge fund is a major shareholder of Beyond Air?
Currently, no hedge funds are holding shares in XAIR
Beyond Air Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.50 (375.11% Upside)
$10.50 (375.11% Upside)
Hedge Fund Trend
Decreased
By 25.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $19.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.00%
12-Months-Change
Fundamentals
Return on Equity
-323.27%
Trailing 12-Months
Asset Growth
-39.54%
Trailing 12-Months
Company Description
Beyond Air
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
XAIR Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance with substantial revenue growth, cost reduction, and international expansion. However, the company faces ongoing net losses and challenges in scaling international sales promptly. The sentiment is cautiously optimistic with positive growth indicators.View all XAIR earnings summariesXAIR Stock 12 Month Forecast
Average Price Target
$10.50
▲(375.11% Upside)
Technical Analysis
Ownership Overview
9.85% Insiders
2.13% Mutual Funds
0.34% Other Institutional Investors
86.13% Public Companies and
Individual Investors